

# Alexander Sedaghat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/964254/publications.pdf>

Version: 2024-02-01

87  
papers

1,997  
citations

304602

22  
h-index

265120

42  
g-index

96  
all docs

96  
docs citations

96  
times ranked

2275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frailty, malnutrition, and the endocrine system impact outcome in patients undergoing aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 145-157.	0.7	4
2	Temporal trends of TAVI treatment characteristics in high volume centers in Germany 2013â€“2020. <i>Clinical Research in Cardiology</i> , 2022, 111, 881-888.	1.5	23
3	Transcatheter Leaflet Strategies for Tricuspid Regurgitation TriClip and CLASP. <i>Interventional Cardiology Clinics</i> , 2022, 11, 51-66.	0.2	0
4	Transverse aortic constriction-induced heart failure leads to increased levels of circulating microparticles. <i>International Journal of Cardiology</i> , 2022, 347, 54-58.	0.8	6
5	Baseline PA/BSA ratio in patients undergoing transcatheter aortic valve replacement â€“ A novel CT-based marker for the prediction of pulmonary hypertension and outcome. <i>International Journal of Cardiology</i> , 2022, 348, 26-32.	0.8	3
6	Haemodynamic differences between two generations of a balloon-expandable transcatheter heart valve. <i>Heart</i> , 2022, 108, 1479-1485.	1.2	4
7	Clinical outcomes of transcatheter aortic valve implantation in patients younger than 70 years rejected for surgery: the AMTRAC registry. <i>EuroIntervention</i> , 2022, 17, 1289-1297.	1.4	7
8	Left atrial function index (LAFI) and outcome in patients undergoing transcatheter aortic valve replacement. <i>Clinical Research in Cardiology</i> , 2022, 111, 944-954.	1.5	2
9	Incidence, persistence, and clinical relevance of iatrogenic atrial septal defects after percutaneous left atrial appendage occlusion. <i>Echocardiography</i> , 2022, 39, 65-73.	0.3	2
10	Percutaneous trans-axilla transcatheter aortic valve replacement. <i>Heart and Vessels</i> , 2022, 37, 1801-1807.	0.5	4
11	Assessment of LAA Strain and Thrombus Mobility and Its Impact on Thrombus Resolutionâ€”Added-Value of a Novel Echocardiographic Thrombus Tracking Method. <i>Cardiovascular Engineering and Technology</i> , 2022, , 1.	0.7	4
12	Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROCC-DRT registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 1276-1285.	1.5	10
13	Clinical outcomes and thrombus resolution in patients with solid left atrial appendage thrombi: results of a single-center real-world registry. <i>Clinical Research in Cardiology</i> , 2021, 110, 72-83.	1.5	12
14	Hemodynamics inside the neoâ€•and native sinus after TAVR: Effects of implant depth and cardiac output on flow field and coronary flow. <i>Artificial Organs</i> , 2021, 45, 68-78.	1.0	17
15	Risk of mortality following transcatheter aortic valve replacement for low-flow low-gradient aortic stenosis. <i>Clinical Research in Cardiology</i> , 2021, 110, 391-398.	1.5	3
16	Risk modeling in transcatheter aortic valve replacement remains unsolved: an external validation study in 2946 German patients. <i>Clinical Research in Cardiology</i> , 2021, 110, 368-376.	1.5	12
17	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCC-DRT-Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010195.	1.4	46
18	CHA2DS2-VASC score predicts coronary artery disease progression and mortality after ventricular arrhythmia in patients with implantable cardioverter-defibrillator. <i>IJC Heart and Vasculature</i> , 2021, 34, 100802.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Large extracellular vesicles in the left atrial appendage in patients with atrial fibrillation—the missing link?. <i>Clinical Research in Cardiology</i> , 2021, , 1.	1.5	2
20	Effect of Transcatheter Aortic Valve Replacement on Concomitant Mitral Regurgitation and Its Impact on Mortality. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1181-1192.	1.1	31
21	Circulating chaperones in patients with aortic valve stenosis undergoing TAVR: impact of concomitant chronic kidney disease. <i>Translational Research</i> , 2021, 233, 117-126.	2.2	2
22	Feasibility and Safety of an 8F Angioseal® Vascular Closure Device for Closure of Large Bore Impella CP® Access. <i>Journal of Endovascular Therapy</i> , 2021, , 152660282110479.	0.8	3
23	Spleen Size and Thrombocytopenia After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 157, 85-92.	0.7	1
24	Incidence, predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device—Insights from the EWOLUTION real world registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E1019-E1024.	0.7	27
25	TCT-271 Outcomes of Transcatheter Aortic Valve Replacement Using Balloon vs Self-Expandable Valves Stratified by Center Valve Preference—Insights From the Multicenter Aortic+Mitral TransCatheter (AMTRAC) Registry. <i>Journal of the American College of Cardiology</i> , 2021, 78, B110-B111.	1.2	0
26	Amplatzer left atrial appendage closure: Single versus combined procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E973-E981.	0.7	4
27	Implications of hydrodynamic testing to guide sizing of self-expanding transcatheter heart valves for valve-in-valve procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E332-E340.	0.7	3
28	Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study. <i>Clinical Research in Cardiology</i> , 2020, 109, 444-453.	1.5	11
29	Percutaneous left atrial appendage closure using the TrueFusion™, a fusion-imaging technology. <i>Clinical Research in Cardiology</i> , 2020, 109, 646-648.	1.5	2
30	Fractional flow reserve in patients with coronary artery disease undergoing TAVI: a prospective analysis. <i>Clinical Research in Cardiology</i> , 2020, 109, 746-754.	1.5	10
31	Healing a Heart of Stone. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 532-533.	1.1	3
32	Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2782-2791.	1.1	29
33	Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2528-2538.	1.1	65
34	A Randomized Trial Comparing Short versus Prolonged Hemostasis with Rescue Recanalization by Ipsilateral Ulnar Artery Compression: Impact on Radial Artery Occlusion—The RESCUE-RAO Trial. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-7.	0.5	4
35	Safety and Efficacy of Protamine Administration for Prevention of Bleeding Complications in Patients Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1471-1480.	1.1	28
36	TAVR outcome after reclassification of aortic valve stenosis by using a hybrid continuity equation that combines computed tomography and echocardiography data. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 958-967.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). <i>American Journal of Cardiology</i> , 2020, 125, 1369-1377.	0.7	15
38	Impact of Tricuspid Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1135-1137.	1.1	12
39	Predictive factors and long-term prognosis of transcatheter aortic valve implantation-associated endocarditis. <i>Clinical Research in Cardiology</i> , 2020, 109, 1165-1176.	1.5	10
40	Outcomes of myocardial fibrosis in patients undergoing transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2020, 15, 1417-1423.	1.4	7
41	Impact of implant depth on hydrodynamic function of the ALLEGRA bioprosthesis in valve-in-valve interventions. <i>EuroIntervention</i> , 2020, 15, e1335-e1342.	1.4	8
42	“One Does Not Simply Walk Into” Valve-in-Valve Implantation in Patients With a Degenerated Stentless Bioprosthesis. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1227-1228.	1.1	0
43	“What you see is what you get”: giant extra-appendage left atrial thrombus after left atrial appendage occlusion for persisting left atrial appendage thrombus. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 21, 465.	0.5	2
44	Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. <i>Lancet, The</i> , 2019, 394, 2002-2011.	6.3	283
45	Intravascular Lithotripsy in Calcified Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008154.	1.4	69
46	Contrast-free, echocardiography-guided left atrial appendage occlusion (LAAo): a propensity-matched comparison with conventional LAAo using the AMPLATZER <sup>®</sup> , Amulet <sup>®</sup> , device. <i>Clinical Research in Cardiology</i> , 2019, 108, 333-340.	1.5	15
47	Early versus newer generation transcatheter heart valves for transcatheter aortic valve implantation: Echocardiographic and hemodynamic evaluation of an all-comers study cohort using the dimensionless aortic regurgitation index (AR-index). <i>PLoS ONE</i> , 2019, 14, e0217544.	1.1	17
48	When past becomes prologue: extremely late mechanical complication after implantation of an atrial septal occluder device. <i>European Heart Journal</i> , 2019, 40, 3657-3657.	1.0	0
49	Fatal Cardioembolic Syndrome Due to Late Device-Related Thrombus After Left Atrial Appendage Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, e91-e92.	1.1	1
50	6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1905-1915.	1.2	172
51	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 433-443.	1.1	59
52	Long-term follow-up after stent graft placement for access-site and access-related vascular injury during TAVI “The Bonn-Copenhagen experience. <i>International Journal of Cardiology</i> , 2019, 281, 42-46.	0.8	17
53	Letter by Sedaghat and Nickenig Regarding Article, “Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes”. <i>Circulation</i> , 2019, 139, 1241-1242.	1.6	2
54	Mechanical properties of currently available left atrial appendage occlusion devices: A bench testing analysis. <i>Artificial Organs</i> , 2019, 43, 656-665.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Predilation in Transcatheter Aortic Valve Implantation. , 2019, , 339-349.		0
56	Mitral meets mortality. Lancet, The, 2018, 391, 916-918.	6.3	1
57	Choosing a Self-Expanding Transcatheter Heart Valve in 2018. JACC: Cardiovascular Interventions, 2018, 11, 2323-2325.	1.1	1
58	Mechanical Performance of Two Left Atrial Appendage Occlusion Systems: In Vitro Comparison of Tug Force, Radial Force, Sealing and Deformation. Annals of Biomedical Engineering, 2018, 46, 1337-1347.	1.3	1
59	Percutaneous treatment of a saccular coronary artery aneurysm using multimodal imaging and rapid prototyping. European Heart Journal, 2018, 39, 4125-4125.	1.0	2
60	In vitro hydrodynamic and acute clinical performance of a novel self-expanding transcatheter heart valve in various surgical bioprostheses. EuroIntervention, 2018, 13, 2014-2017.	1.4	8
61	Transcatheter aortic valve implantation leads to a restoration of von Willebrand factor (VWF) abnormalities in patients with severe aortic stenosis – Incidence and relevance of clinical and subclinical VWF dysfunction in patients undergoing transfemoral TAVI. Thrombosis Research, 2017, 151, 23-28.	0.8	25
62	Reply. JACC: Clinical Electrophysiology, 2017, 3, 190-191.	1.3	0
63	Reply. JACC: Clinical Electrophysiology, 2017, 3, 192-193.	1.3	0
64	Periprocedural Myocardial Injury Depends on Transcatheter Heart Valve Type But Does Not Predict Mortality in Patients After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1550-1560.	1.1	33
65	Thrombus Formation After Left Atrial Appendage Occlusion With the Amplatzer Atrial Septal Occluder Device. JACC: Clinical Electrophysiology, 2017, 3, 71-75.	1.3	41
66	Pre-Procedural Hemodynamic Status Improves the Discriminatory Value of Aortic Regurgitation Index in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 700-711.	1.1	33
67	Reply. Annals of Thoracic Surgery, 2016, 102, 350.	0.7	0
68	Routine Endovascular Treatment With a Stent Graft for Access-Site and Access-Related Vascular Injury in Transfemoral Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	29
69	TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia. International Journal of Cardiology, 2016, 221, 719-725.	0.8	21
70	Circulating Microparticles Decrease After Cardiac Stress in Patients With Significant Coronary Artery Stenosis. Clinical Cardiology, 2016, 39, 570-577.	0.7	8
71	Valve-in-valve outcome: design impact of a pre-existing bioprosthesis on the hydrodynamics of an Edwards Sapien XT valve. European Journal of Cardio-thoracic Surgery, 2016, 51, ezw317.	0.6	12
72	Hydrodynamic Performance of the Medtronic CoreValve and the Edwards SAPIEN XT Transcatheter Heart Valve in Surgical Bioprostheses: An In Vitro Valve-in-Valve Model. Annals of Thoracic Surgery, 2016, 101, 118-124.	0.7	22

#	ARTICLE	IF	CITATIONS
73	Balloon post-dilation and valve-in-valve implantation for the reduction of paravalvular leakage with use of the self-expanding CoreValve prosthesis. <i>EuroIntervention</i> , 2016, 11, 1140-1147.	1.4	17
74	Outcome in <sc>TAVI</sc> patients with symptomatic aortic stenosis not fulfilling <sc>PARTNER</sc> study inclusion criteria. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1097-1104.	0.7	9
75	Right heart transcatheter valve therapies – a review of prostheses for the pulmonary and tricuspid positions. <i>Expert Review of Medical Devices</i> , 2015, 12, 163-174.	1.4	2
76	Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2015, 170, 821-829.	1.2	43
77	Use of a balloon-expandable transfemoral sheath in a TAVI cohort with complex access site - a propensity score matched analysis. <i>EuroIntervention</i> , 2015, 11, 698-704.	1.4	7
78	Left atrial appendage closure in a patient with atrial fibrillation after mechanical mitral valve replacement and cardio-embolic stroke despite effective oral anticoagulant therapy: a case report. <i>Clinical Research in Cardiology</i> , 2014, 103, 587-589.	1.5	5
79	In vitro assessment of the influence of aortic annulus ovality on the hydrodynamic performance of self-expanding transcatheter heart valve prostheses. <i>Journal of Biomechanics</i> , 2014, 47, 957-965.	0.9	37
80	Doppler-based renal resistance index for the detection of acute kidney injury and the non-invasive evaluation of paravalvular aortic regurgitation after transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2014, 9, 1309-1316.	1.4	22
81	Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2014, 9, 1042-1049.	1.4	71
82	Influence of the Measurement Plane on Aortic Annulus Indices: Structural and Clinical Implications. <i>Cardiovascular Engineering and Technology</i> , 2013, 4, 513-519.	0.7	1
83	The revised EuroSCORE II for the prediction of mortality in patients undergoing transcatheter aortic valve implantation. <i>Clinical Research in Cardiology</i> , 2013, 102, 821-829.	1.5	47
84	First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model. <i>Clinical Research in Cardiology</i> , 2013, 102, 413-425.	1.5	32
85	First experience with a new balloon-expandable and re-collapseable vascular sheath in transfemoral percutaneous aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E613-6.	0.7	6
86	Aortic Regurgitation Index Defines Severity of Peri-Prosthetic Regurgitation and Predicts Outcome in Patients After Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1134-1141.	1.2	371
87	TCT-823 In-Vitro Assessment Of The Influence Of Oval Annuli On The Hydrodynamic Function Of Percutaneous Heart Valve Prostheses. <i>Journal of the American College of Cardiology</i> , 2012, 60, B239.	1.2	1